Condition: Locally Advanced Head and Neck Carcinoma · Sponsor: Centre Jean Perrin
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment
This description comes directly from the study's public registry record.
Angeline GINZAC COUVÉ Project manager, PhD · 0463663337 · angeline.ginzac@clermont.unicancer.fr
Always discuss trial participation with your own doctor first.
| CH Henri Mondor Aurillac | Aurillac, CANTAL, France | Recruiting |
| Centre Jean PERRIN | Clermont-Ferrand, Puy-de-Dôme, France | Recruiting |
| Hôpital de la Croix-Rousse | Lyon, France | Recruiting |
| CHU de Saint-Étienne | Saint-Etienne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07178847